> Detailanzeige

Snee, Michael; Cheeseman, Sue; Thompson, Matthew; Riaz, Majid; Sopwith, Will; Lacoin, Laure; Chaib, Carlos; J Daumont, Melinda; Penrod, John R; O’Donnell, John C; Hall, Geoff

Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative
  • Beteiligte: Snee, Michael; Cheeseman, Sue; Thompson, Matthew; Riaz, Majid; Sopwith, Will; Lacoin, Laure; Chaib, Carlos; J Daumont, Melinda; Penrod, John R; O’Donnell, John C; Hall, Geoff
  • Erschienen: BMJ, 2021
  • Erschienen in: BMJ Open
  • Sprache: Englisch
  • DOI: 10.1136/bmjopen-2020-043442
  • ISSN: 2044-6055
  • Schlagwörter: General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Objectives</jats:title><jats:p>To assess how a decade of developments in systematic anticancer therapy (SACT) for advanced non-small cell lung cancer (NSCLC) affected overall survival (OS) in a large UK University Hospital.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>Real-world retrospective observational cohort study using existing data recorded in electronic medical records.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>A large National Health Service (NHS) university teaching hospital serving 800 000 people living in a diverse metropolitan area of the UK.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>2119 adults diagnosed with advanced NSCLC (tumour, node, metastasis stage IIIB or IV) between 2007 and 2017 at Leeds Teaching Hospitals NHS Trust.</jats:p></jats:sec><jats:sec><jats:title>Main outcomes and measures</jats:title><jats:p>OS following diagnosis and the analysis of factors associated with receiving SACT.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Median OS for all participants was 2.9 months, increasing for the SACT-treated subcohort from 8.4 months (2007–2012) to 9.1 months (2013–2017) (p=0.02); 1-year OS increased from 33% to 39% over the same period for the SACT-treated group. Median OS for the untreated subcohort was 1.6 months in both time periods. Overall, 30.6% (648/2119) patients received SACT; treatment rates increased from 28.6% (338/1181) in 2007–2012 to 33.0% (310/938) in 2013–2017 (p=0.03). Age and performance status were independent predictors for SACT treatment; advanced age and higher performance status were associated with lower SACT treatment rates.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Although developments in SACT during 2007–2017 correspond to some changes in survival for treated patients with advanced NSCLC, treatment rates remain low and the prognosis for all patients remains poor.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang